Akebia Therapeutics Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Akebia Therapeutics, Inc. (Nasdaq: AKBA), dedicated to improving the lives of those with kidney disease, will have its CEO John P. Butler and CFO David A. Spellman participate in several investor conferences. Key events include the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, where Butler will attend a virtual fireside chat, and the 4th Annual Evercore ISI HealthCONx Conference from November 30 to December 2, featuring another fireside chat by Butler on November 30 at 4:45 PM. Webcasts will be available on the company's website.

News Market Reaction – AKBA

+1.45%

+1.45% Session move

In the trading session that priced this news, AKBA gained 1.45%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following investor conferences:

Piper Sandler 33^rd Annual Virtual Healthcare Conference
November 29 – December 2, 2021
John Butler will participate in a virtual fireside chat, which will be available on the conference site prior to the virtual event. 

4^th Annual Evercore ISI HealthCONx Conference
November 30 - December 2, 2021
John Butler will participate in a virtual fireside chat, which will be presented on Tuesday, November 30 at 4:45 on the conference site.

Where applicable, webcasts of Akebia's fireside chats will be made available on the Investors section of the Company's website at https://ir.akebia.com.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
Mcarrasco@akebia.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-participation-in-upcoming-investor-conferences-301431123.html

SOURCE Akebia Therapeutics

FAQ

What investor conferences is Akebia Therapeutics participating in November 2021?

Akebia Therapeutics will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, and the 4th Annual Evercore ISI HealthCONx Conference from November 30 to December 2, 2021.

Who from Akebia Therapeutics will speak at the upcoming conferences?

John P. Butler, CEO, and David A. Spellman, CFO, will represent Akebia Therapeutics at the upcoming investor conferences.

When will John P. Butler speak at the Evercore ISI HealthCONx Conference?

John P. Butler will participate in a virtual fireside chat at the Evercore ISI HealthCONx Conference on November 30, 2021, at 4:45 PM.

Where can I find the webcasts for Akebia's presentations?

Webcasts of Akebia Therapeutics' fireside chats will be available on the Investors section of their website at https://ir.akebia.com.

What is the purpose of Akebia Therapeutics?

Akebia Therapeutics aims to better the lives of people impacted by kidney disease through the development and commercialization of therapeutics.